Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | XPO1 | O14980 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324269 | 0.85 | TBXA2R (0.41) | DRD4SIGMAR1CXCR3ADRA1DADRA1A | |
| SCHEMBL13324268 | 0.85 | KCNA3 (0.49) | DRD4CXCR3XPO1 | |
| SCHEMBL13324277 | 0.82 | TBXA2R (0.43) | DRD4ADRA1DADRA1AADRA1BXPO1 | |
| Hydrochloric Acid SCHEMBL3281041 | 0.81 | TBXA2R (0.42) | DRD4ADRA1DADRA1AADRA1BXPO1 | |
| SCHEMBL3936968 | 0.79 | DRD4 (0.63) | DRD4SIGMAR1CXCR3ADRA2AADRA2B | |
| SCHEMBL4664306 | 0.79 | XPO1 (0.40) | DRD4SIGMAR1ADRA2BADRA2CADRA1A | |
| SCHEMBL5709511 | 0.74 | SIGMAR1 (0.60) | DRD4SIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL3285006 | 0.73 | KCNH2 (0.55) | — | |
| SCHEMBL3937679 | 0.72 | DRD4 (0.69) | DRD4SIGMAR1CXCR3 | |
| SCHEMBL27430491 | 0.72 | SIGMAR1 (0.79) | DRD4SIGMAR1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709496-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20090054418-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054418-A1 | Antibacterial Agents | MRPL21, ELANE, SPOUT1 | DRD4 2479/4885SIGMAR1 1144/4885CXCR3 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.